Corynebacterium group D2 urinary tract infection
Abstract
An unusual multiply resistant corynebacterium was isolated from the urine of a comatose patient. This organism was resistant to sulphafurazole, trimethoprim, nalidixic acid, cefazolin, nitrofurantoin, clindamycin, erythromycin, oxacillin, penicillin, gentamicin, amikacin, cinoxacin, ceftazidime and cefotaxime, but was susceptible to ciprofloxacin, ofloxacin, norfloxacin, vancomycin and fucidin. It was identified as the first reported isolate in South Africa of corynebacterium group D2, an organism recently implicated in alkaline-encrusted cystitis and urinary tract infection. We discuss the case history of the patient and review the literature.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.